About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
The authors explain the benefits of ACE-inhibitors in controlling the progression of renal disease.
Tomoko Terajima, MS Pharm, Shin-ichi Yamagata, MS Pharm, Nobunori Satoh, PhD, and Shiro Ueda, MD
A family practitioner discovers some of the lessons to be learned from treating a terminally ill patient.
Thomas Marzili, MD
The author reviews ezetimibe for lowering blood lipid levels, atomoxetine for attention-deficit hyperactivity disorder, and injectable teriparatide for osteoporosis.
Marvin M. Goldenberg, PhD
Letter to the Editor
Drug companies can satisfy their customers by responding to their increasing demands for information.
The authors discuss a new topical therapeutic agent for the treatment of genital warts and other skin conditions.
David J. Najarian, BS, and Joseph C. English III, MD
Editor-in-Chief Dr. David Nash reports on California’s Integrated Healthcare Association.
David B. Nash, MD, MBA
Matthew Grissinger describes the potential pitfalls of pharmacy computer-generated medication administration records.
The latest information about approvals, indication changes, industry updates, and news from the FDA.
Stephen Barlas discusses the FDA’s latest proposal on generic drugs.
Drs. Kleyman and Sisca review eplerenone for the treatment of hypertension.
Jennie Kleyman, PharmD, and Thomas S. Sisca, PharmD
Both ACE-inhibitors and beta blockers are commonly prescribed for patients with hypertension, but the numbers are changing.